{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-048579","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.279567+00:00","generated_at":"2026-05-21T08:57:06.447990+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Quoin Pharma Q1 net loss $3.8M; positive QRX003 data and patent expansion","bullets":["Cash of $11.6M at March 31, 2025; expected to fund operations into Q1 2026.","Net loss of $3.8M for Q1 2025, versus $2.3M in Q1 2024.","QRX003 showed reversal of clinical benefits upon discontinuation, confirming mechanism of action.","Patent applications filed for topical rapamycin and novel QRX003 formulations, extending IP to 2045.","FDA-cleared whole-body QRX003 study at Northwestern University for 8-12 Netherton patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-048579","json":"https://secwatch.observer/filing/0001104659-25-048579.json","markdown":"https://secwatch.observer/filing/0001104659-25-048579.md","text":"https://secwatch.observer/filing/0001104659-25-048579.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465925048579/0001104659-25-048579-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465925048579/tm2515088d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T08:57:06.447990+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}